Further Reading (optional)
Further Reading (optional)
If you would like to learn more about this topic, we recommend you to visit the following:
- Epigenetics - here and here
- Proteomics technologies - here and here
- Biomarkers in drug development - Waterton JC, Pylkkanen L. Qualification of imaging biomarkers for oncology drug development. European Journal Cancer 2012:48; 409-415 - here
- Principle of the Sanger method of DNA sequencing - here
- EMA Note for guidance on definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. November 2007 - here
- The International Human Genome Mapping Consortium (2001) A physical map of the human genome Nature 409, 934-941 - here
- Green EM, Gozani O. Everybody’s welcome: the big tent approach to epigenetic drug discovery. Drug Discovery Today: Therapeutic Strategies. 2012; 9: e75-e81- here
- Qualification opinion of low hippocampal volume (atrophy) by MRI for use in regulatory clinical trials - in pre-dementia stage of Alzheimer’s disease- here
- Fact Sheet on Gene therapy produced by the Centre for Genetics Education (Australia) - here
- European Medicines Agency stance on stem cell research - here
- European Medicines Agency Committee for Advanced Therapies (CAT) - Use of unregulated stem-cell based medicinal products - here